Sexual dysfunction in women with breast cancer: a systematic review.

IF 2.8 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Supportive Care in Cancer Pub Date : 2025-03-31 DOI:10.1007/s00520-025-09352-6

Nelson Rodrigues-Machado, Xavier Bonfill-Cosp, M Jesús Quintana, Marilina Santero, Ana Bártolo, Anna Selva Olid

{"title":"Sexual dysfunction in women with breast cancer: a systematic review.","authors":"Nelson Rodrigues-Machado, Xavier Bonfill-Cosp, M Jesús Quintana, Marilina Santero, Ana Bártolo, Anna Selva Olid","doi":"10.1007/s00520-025-09352-6","DOIUrl":null,"url":null,"abstract":"Purpose: This systematic review aims to assess the prevalence, incidence, and risk factors for sexual dysfunction (SdF) in women with breast cancer (BC).Methods: A systematic search was conducted in MEDLINE (PubMed), PsycINFO, Web of Science, and CINAHL to identity longitudinal, observational studies assessing SdF in women with BC. Data extraction followed PRISMA guidelines. The Joanna Briggs Institute checklist was used to assess methodological quality. Results were narratively synthesised.Results: A total of 16 studies involving 4058 women met the inclusion criteria. Overall, the reported prevalence of SdF ranged from 17.5% before BC diagnosis to 86% after 6 months of hormone therapy. Only one study reported incidence data. The six most commonly studied SdF domains were desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia. A significant number of risk factors associated with different dimensions of SdF were identified.Conclusion: SdF is highly prevalent in women with BC, particularly in the first year after diagnosis and treatment. These findings strongly suggest that SdF should be routinely assessed as part of survivorship care protocols. Due to the scant data on incidence rates and the wide variability in reported risk factors, significant gaps remain in our understanding of the onset and progression of SdF in patients with BC. Well-designed cohort studies are needed to better establish the incidence and aetiology of SdF in this patient population.","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 4","pages":"332"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958476/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Supportive Care in Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00520-025-09352-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This systematic review aims to assess the prevalence, incidence, and risk factors for sexual dysfunction (SdF) in women with breast cancer (BC).

Methods: A systematic search was conducted in MEDLINE (PubMed), PsycINFO, Web of Science, and CINAHL to identity longitudinal, observational studies assessing SdF in women with BC. Data extraction followed PRISMA guidelines. The Joanna Briggs Institute checklist was used to assess methodological quality. Results were narratively synthesised.

Results: A total of 16 studies involving 4058 women met the inclusion criteria. Overall, the reported prevalence of SdF ranged from 17.5% before BC diagnosis to 86% after 6 months of hormone therapy. Only one study reported incidence data. The six most commonly studied SdF domains were desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia. A significant number of risk factors associated with different dimensions of SdF were identified.

Conclusion: SdF is highly prevalent in women with BC, particularly in the first year after diagnosis and treatment. These findings strongly suggest that SdF should be routinely assessed as part of survivorship care protocols. Due to the scant data on incidence rates and the wide variability in reported risk factors, significant gaps remain in our understanding of the onset and progression of SdF in patients with BC. Well-designed cohort studies are needed to better establish the incidence and aetiology of SdF in this patient population.

查看原文本刊更多论文

乳腺癌女性性功能障碍：一项系统综述。

目的：本系统综述旨在评估乳腺癌（BC）女性性功能障碍（SdF）的患病率、发病率和危险因素。方法：在MEDLINE （PubMed）、PsycINFO、Web of Science和CINAHL中进行系统搜索，以确定评估BC女性SdF的纵向观察性研究。数据提取遵循PRISMA指南。乔安娜布里格斯研究所的检查表被用来评估方法学的质量。结果被叙述合成。结果：共有16项研究4058名女性符合纳入标准。总体而言，报告的SdF患病率从BC诊断前的17.5%到激素治疗6个月后的86%不等。只有一项研究报告了发病率数据。最常被研究的六个SdF域是欲望、觉醒、润滑、高潮、满足和性交困难。确定了与不同维度的SdF相关的大量危险因素。结论：SdF在BC患者中非常普遍，特别是在诊断和治疗后的第一年。这些发现强烈建议将SdF作为生存护理方案的一部分进行常规评估。由于关于发病率的数据不足和报道的危险因素的广泛差异，我们对BC患者SdF的发生和进展的理解仍然存在重大差距。需要精心设计的队列研究来更好地确定该患者群体中SdF的发病率和病因。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Supportive Care in Cancer 医学-康复医学

CiteScore

5.70

自引率

9.70%

发文量

751

审稿时长

3 months

期刊介绍： Supportive Care in Cancer provides members of the Multinational Association of Supportive Care in Cancer (MASCC) and all other interested individuals, groups and institutions with the most recent scientific and social information on all aspects of supportive care in cancer patients. It covers primarily medical, technical and surgical topics concerning supportive therapy and care which may supplement or substitute basic cancer treatment at all stages of the disease. Nursing, rehabilitative, psychosocial and spiritual issues of support are also included.